Previous 10 | Next 10 |
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU ™ in wet AMD in 2H 2024 – – $299 million of cash and investments on March 31, 2024, with cash runway through topline data of Phase 3 trials for DURAVYU...
2024-05-07 12:50:20 ET Summary Despite NPDR primary endpoint miss, potential exists with EyePoint Pharmaceuticals releasing 12-month phase 2 PAVIA data; potential for continued advancement depending upon data. LUGANO and LUCIA are two pivotal phase 3 studies expected to be initiat...
A look at the top 10 most actives in the United States Palantir Technologies Inc. Class A (PLTR) rose 8.1% to $25.21 on volume of 141,121,870 shares Lyra Therapeutics Inc. (LYRA) fell 87.1% to $0.5215 on volume of 107,579,343 shares PROSHARES TRUST (SQQQ) fell 3.4% to $10.7 on volume of 9...
2024-05-06 14:21:52 ET Summary EyePoint Pharmaceuticals, Inc. stock surged following positive Phase 2 trial outcomes in wet AMD, showing non-inferiority to Eylea. Despite success in wet AMD, 1901 showed disappointing results in an NPDR trial, failing its primary endpoint. Fina...
2024-05-06 13:17:53 ET More on Mid-day movers & stocks. Manitex International, Inc. 2024 Q1 - Results - Earnings Call Presentation Manitex International, Inc. (MNTX) Q1 2024 Earnings Call Transcript Manitex International, Inc. (MNTX) Q4 2023 Earnings Call Transcr...
2024-05-06 10:01:41 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
A look at the top 10 most actives in the United States XBP Europe Holdings Inc. (XBP) rose 69.1% to $3.5846 on volume of 37,660,870 shares Lyra Therapeutics Inc. (LYRA) fell 90.2% to $0.3942 on volume of 21,985,500 shares NIO Inc. American depositary shares each representing one Class A (...
2024-05-06 09:24:05 ET EyePoint Pharmaceuticals ( NASDAQ: EYPT ) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase 2 study for its eye drug Duravyu, also known as EYP-1901, failed to meet its primary endpoint in the treatment of non-proliferative di...
2024-05-06 08:26:44 ET More on pre-market losers & stocks. GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come Predictive Oncology Inc. (POAI) Q4 2023 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...
2024-06-11 11:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...